INTRODUCTION

1. OECD Guidelines for the Testing of Chemicals are periodically reviewed in light of scientific progress, changing regulatory needs, and animal welfare considerations. The original Test Guideline (TG) for the determination of skin sensitization in the mouse, the Local Lymph Node Assay (LLNA; TG 429) was adopted in 2002 (1). The details of the validation of the LLNA and a review of the associated work have been published (2) (3) (4) (5) (6) (7) (8) (9) (10) (11). The updated LLNA is based on the evaluation of experience and scientific data (12). This is the second TG to be designed for assessing skin sensitization potential of chemicals in animals. The other TG (i.e. TG 406) utilises guinea pig tests, notably the guinea pig maximisation test and the Buehler test (13). The LLNA provides advantages over TG 406 (13) with regard to animal welfare. This updated LLNA TG includes a set of Performance Standards (PS) (Annex 1) that can be used to evaluate the validation status of new and/or modified test methods that are functionally and mechanistically similar to the LLNA, in accordance with the principles of Guidance Document No. 34 (14).

2. The LLNA studies the induction phase of skin sensitization and provides quantitative data suitable for dose-response assessment. It should be noted that the mild/moderate sensitizers which are recommended as suitable positive control (PC) test substances for guinea pig test methods (i.e. TG 406) (13) are also appropriate for use with the LLNA (6) (8) (15). A reduced LLNA (rLLNA) approach, which could use up to 40% fewer animals is also described as an option in this TG (16) (17) (18). The rLLNA may be used when there is a regulatory need to confirm a negative prediction of skin sensitizing potential, provided there is adherence to all other LLNA protocol specifications, as described in this Test Guideline. Prediction of a negative outcome should be made based on all available information as described in paragraph 4. Before applying the rLLNA approach, clear justifications and scientific rationale for its use should be provided. If, against expectations, a positive or equivocal result is obtained in the rLLNA, additional testing may be needed in order to interpret or clarify the finding. The rLLNA should not be used for the hazard identification of skin sensitising test substances when dose-response information is needed, such as sub-categorisation for UN Globally Harmonized System of classification and Labelling of Chemicals.

DEFINITIONS

3. Definitions used are provided in Annex 2.

INITIAL CONSIDERATIONS AND LIMITATIONS

4. The LLNA provides an alternative method for identifying potential skin sensitizing test substances. This does not necessarily imply that in all instances the LLNA should be used in place of guinea pig tests (i.e. TG 406) (13), but rather that the assay is of equal merit and may be employed as an alternative in which positive and negative results generally no longer require further confirmation. The testing laboratory should consider all available information on the test substance prior to conducting the study. Such information will include the identity and chemical structure of the test substance; its physicochemical properties; the results of any other in vitro or in vivo toxicity tests on the test substance;
and toxicological data on structurally related test substances. This information should be considered in
order to determine whether the LLNA is appropriate for the test substance (given the incompatibility of
limited types of test substances with the LLNA- see paragraph 5) and to aid in dose selection.

5. The LLNA is an \( \textit{in vivo} \) method and, as a consequence, will not eliminate the use of animals in
the assessment of allergic contact sensitizing activity. It has, however, the potential to reduce the number
of animals required for this purpose. Moreover, the LLNA offers a substantial refinement (less pain and
distress) of the way in which animals are used for allergic contact sensitization testing. The LLNA is based
upon consideration of immunological events stimulated by chemicals during the induction phase of
sensitization. Unlike guinea pig tests (\textit{i.e.} TG 406) (13) the LLNA does not require that challenge-induced
dermal hypersensitivity reactions be elicited. Furthermore, the LLNA does not require the use of an
adjuvant, as is the case for the guinea pig maximisation test (13). Thus, the LLNA reduces animal pain and
distress. Despite the advantages of the LLNA over TG 406, it should be recognised that there are certain
limitations that may necessitate the use of TG 406 (13) (\textit{e.g.} false negative findings in the LLNA with
certain metals, false positive findings with certain skin irritants [such as some surfactant type chemicals]
(19) (20), or solubility of the test substance). In addition, test substance classes or substances containing
functional groups shown to act as potential confounders (21) may necessitate the use of guinea pig tests
(\textit{i.e.} TG 406) (13). Further, based on the limited validation database, which consisted primarily of pesticide
formulations, the LLNA is more likely than the guinea pig test to yield a positive result for these types of
test substances (22). However, when testing formulations, one could consider including similar test
substances with known results as benchmark test substances to demonstrate that the LLNA is functioning
properly (see paragraph 16). Other than such identified limitations, the LLNA should be applicable for
testing any test substances unless there are properties associated with these test substances that may
interfere with the accuracy of the LLNA.

**PRINCIPLE OF THE TEST**

6. The basic principle underlying the LLNA is that sensitizers induce proliferation of lymphocytes
in the lymph nodes draining the site of test substance application. This proliferation is proportional to the
dose and to the potency of the applied allergen and provides a simple means of obtaining a quantitative
measurement of sensitization. Proliferation is measured by comparing the mean proliferation in each test
group to the mean proliferation in the vehicle treated control (VC) group. The ratio of the mean
proliferation in each treated group to that in the concurrent VC group, termed the Stimulation Index (SI), is
determined, and should be \( \geq 3 \) before classification of the test substance as a potential skin sensitizer is
warranted. The methods described here are based on the use of \( \textit{in vivo} \) radioactive labelling to measure an
increased number of proliferating cells in the draining auricular lymph nodes. However, other endpoints
for assessment of the number of proliferating cells may be employed provided the PS requirements are
fully met (Annex 1).

**DESCRIPTION OF THE ASSAY**

*Selection of animal species*

7. The mouse is the species of choice for this test. Young adult female mice of CBA/Ca or CBA/J
strain, which are nulliparous and non-pregnant, are used. At the start of the study, animals should be
between 8-12 weeks old, and the weight variation of the animals should be minimal and not exceed 20% of
the mean weight. Alternatively, other strains and males may be used when sufficient data are generated to
demonstrate that significant strain and/or gender-specific differences in the LLNA response do not exist.

*Housing and feeding conditions*
8. Mice should be group-housed (23), unless adequate scientific rationale for housing mice individually is provided. The temperature of the experimental animal room should be 22 ± 3°C. Although the relative humidity should be at least 30% and preferably not exceed 70%, other than during room cleaning, the aim should be 50-60%. Lighting should be artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional laboratory diets may be used with an unlimited supply of drinking water.

**Preparation of animals**

9. The animals are randomly selected, marked to permit individual identification (but not by any form of ear marking), and kept in their cages for at least five days prior to the start of dosing to allow for acclimatisation to the laboratory conditions. Prior to the start of treatment all animals are examined to ensure that they have no observable skin lesions.

**Preparation of dosing solutions**

10. Solid test substances should be dissolved or suspended in solvents/vehicles and diluted, if appropriate, prior to application to an ear of the mice. Liquid test substances may be applied neat or diluted prior to dosing. Insoluble substances, such as those generally seen in medical devices, should be subjected to an exaggerated extraction in an appropriate solvent to reveal all extractable constituents for testing prior to application to an ear of the mice. Test substances should be prepared daily unless stability data demonstrate the acceptability of storage.

**Reliability check**

11. Positive controls are used to demonstrate appropriate performance of the assay by responding with adequate and reproducible sensitivity to a sensitising test substance for which the magnitude of the response is well characterised. Inclusion of a concurrent PC is recommended because it demonstrates competency of the laboratory to successfully conduct each assay and allows for an assessment of intra-, and inter-laboratory reproducibility and comparability. A PC for each study is also required by some regulatory authorities and therefore users are encouraged to consult the relevant authorities prior to conducting the LLNA. Accordingly, the routine use of a concurrent PC is encouraged to avoid the need for additional animal testing to meet such requirements that might arise from the use of a periodic PC (see paragraph 12). The PC should produce a positive LLNA response at an exposure level expected to give an increase in the SI > 3 over the negative control (NC) group. The PC dose should be chosen such that it does not cause excessive skin irritation or systemic toxicity and the induction is reproducible but not excessive (i.e. SI > 20). Preferred PC test substances are 25% hexyl cinnamic aldehyde (Chemical Abstracts Service [CAS] No 101-86-0) in acetone: olive oil (4:1, v/v) and 5% mercaptobenzothiazole (CAS No 149-30-4) in N,N-dimethylformamide (see Annex 1, Table 1). There may be circumstances in which, given adequate justification, other PC test substances, meeting the above criteria, may be used.

12. While inclusion of a concurrent PC group is recommended, there may be situations in which periodic testing (i.e. at intervals ≤ 6 months) of the PC test substance may be adequate for laboratories that conduct the LLNA regularly (i.e. conduct the LLNA at a frequency of no less than once per month) and have an established historical PC database that demonstrates the laboratory’s ability to obtain reproducible and accurate results with PCs. Adequate proficiency with the LLNA can be successfully demonstrated by generating consistent positive results with the PC in at least 10 independent tests conducted within a reasonable period of time (i.e. less than one year).

13. A concurrent PC group should always be included when there is a procedural change to the LLNA (e.g. change in trained personnel, change in test method materials and/or reagents, change in test
method equipment, change in source of test animals), and such changes should be documented in laboratory reports. Consideration should be given to the impact of these changes on the adequacy of the previously established historical database in determining the necessity for establishing a new historical database to document consistency in the PC results.

14. Investigators should be aware that the decision to conduct a PC study on a periodic basis instead of concurrently has ramifications on the adequacy and acceptability of negative study results generated without a concurrent PC during the interval between each periodic PC study. For example, if a false negative result is obtained in the periodic PC study, negative test substance results obtained in the interval between the last acceptable periodic PC study and the unacceptable periodic PC study may be questioned. Implications of these outcomes should be carefully considered when determining whether to include concurrent PCs or to only conduct periodic PCs. Consideration should also be given to using fewer animals in the concurrent PC group when this is scientifically justified and if the laboratory demonstrates, based on laboratory-specific historical data, that fewer mice can be used (12).

15. Although the PC test substance should be tested in the vehicle that is known to elicit a consistent response (e.g. acetone: olive oil; 4:1, v/v), there may be certain regulatory situations in which testing in a non-standard vehicle (clinically/chemically relevant formulation) will also be necessary (24). If the concurrent PC test substance is tested in a different vehicle than the test substance, then a separate VC for the concurrent PC should be included.

16. In instances where test substances of a specific chemical class or range of responses are being evaluated, benchmark test substances may also be useful to demonstrate that the test method is functioning properly for detecting the skin sensitisation potential of these types of test substances. Appropriate benchmark test substances should have the following properties:

- structural and functional similarity to the class of the test substance being tested;
- known physical/chemical characteristics;
- supporting data from the LLNA;
- supporting data from other animal models and/or from humans.

**TEST PROCEDURE**

**Number of animals and dose levels**

17. A minimum of four animals is used per dose group, with a minimum of three concentrations of the test substance, plus a concurrent NC group treated only with the vehicle for the test substance, and a PC (concurrent or recent, based on laboratory policy in considering paragraphs 11-15). Testing multiple doses of the PC should be considered, especially when testing the PC on an intermittent basis. Except for absence of treatment with the test substance, animals in the control groups should be handled and treated in a manner identical to that of animals in the treatment groups.

18. Dose and vehicle selection should be based on the recommendations given in references (3) and (5). Consecutive doses are normally selected from an appropriate concentration series such as 100%, 50%, 25%, 10%, 5%, 2.5%, 1%, 0.5%, etc. Adequate scientific rationale should accompany the selection of the concentration series used. All existing toxicological information (e.g. acute toxicity and dermal irritation) and structural and physicochemical information on the test substance of interest (and/or structurally related test substances) should be considered where available, in selecting the three consecutive concentrations so that the highest concentration maximises exposure while avoiding systemic toxicity and/or excessive local
skin irritation (3) (25). In the absence of such information, an initial pre-screen test may be necessary (see paragraphs 21-24).

19. The vehicle should not interfere with or bias the test result and should be selected on the basis of maximising the solubility in order to obtain the highest concentration achievable while producing a solution/suspension suitable for application of the test substance. Recommended vehicles are acetone: olive oil (4:1, v/v), N,N-dimethylformamide, methyl ethyl ketone, propylene glycol, and dimethyl sulphoxide (19) but others may be used if sufficient scientific rationale is provided. In certain situations it may be necessary to use a clinically relevant solvent or the commercial formulation in which the test substance is marketed as an additional control. Particular care should be taken to ensure that hydrophilic substances are incorporated into a vehicle system, which wets the skin and does not immediately run off, by incorporation of appropriate solubilisers (e.g. 1% Pluronic® L92). Thus, wholly aqueous vehicles are to be avoided.

20. The processing of lymph nodes from individual mice allows for the assessment of inter-animal variability and a statistical comparison of the difference between test substance and VC group measurements (see paragraph 35). In addition, evaluating the possibility of reducing the number of mice in the PC group is feasible when individual animal data are collected (12). Further, some national regulatory authorities require the collection of individual animal data. Nonetheless, pooled animal data may be considered acceptable by some regulatory authorities and in such situations, users may have the option of collecting either individual or pooled animal data.

Pre-screen test

21. In the absence of information to determine the highest dose to be tested (see paragraph 18), a pre-screen test should be performed in order to define the appropriate dose level to test in the LLNA. The purpose of the pre-screen test is to provide guidance for selecting the maximum dose level to use in the main LLNA study, where information on the concentration that induces systemic toxicity (see paragraph 24) and/or excessive local skin irritation (see paragraph 23) is not available. The maximum dose level tested should be 100% of the test substance for liquids or the maximum possible concentration for solids or suspensions.

22. The pre-screen test is conducted under conditions identical to the main LLNA study, except there is no assessment of lymph node proliferation and fewer animals per dose group can be used. One or two animals per dose group are suggested. All mice will be observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights are recorded pre-test and prior to termination (Day 6). Both ears of each mouse are observed for erythema and scored using Table 1 (25). Ear thickness measurements are taken using a thickness gauge (e.g. digital micrometer or Peacock Dial thickness gauge) on Day 1 (pre-dose), Day 3 (approximately 48 hours after the first dose), and Day 6. Additionally, on Day 6, ear thickness could be determined by ear punch weight determinations, which should be performed after the animals are humanely killed. Excessive local skin irritation is indicated by an erythema score ≥3 and/or an increase in ear thickness of ≥25% on any day of measurement (26) (27). The highest dose selected for the main LLNA study will be the next lower dose in the pre-screen concentration series (see paragraph 18) that does not induce systemic toxicity and/or excessive local skin irritation.

Table 1: Erythema Scores

<table>
<thead>
<tr>
<th>Observation</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No erythema</td>
<td>0</td>
</tr>
<tr>
<td>Very slight erythema (barely perceptible)</td>
<td>1</td>
</tr>
<tr>
<td>Well-defined erythema</td>
<td>2</td>
</tr>
<tr>
<td>Moderate to severe erythema</td>
<td>3</td>
</tr>
</tbody>
</table>
23. In addition to a 25% increase in ear thickness (26) (27), a statistically significant increase in ear thickness in the treated mice compared to control mice has also been used to identify irritants in the LLNA (28) (29) (30) (31) (32) (33) (34). However, while statistically significant increases can occur when ear thickness is less than 25% they have not been associated specifically with excessive irritation (30) (32) (33) (34).

24. The following clinical observations may indicate systemic toxicity (35)(36) when used as part of an integrated assessment and therefore may indicate the maximum dose level to use in the main LLNA: changes in nervous system function (e.g. pilo-erection, ataxia, tremors, and convulsions); changes in behaviour (e.g. aggressiveness, change in grooming activity, marked change in activity level); changes in respiratory patterns (i.e. changes in frequency and intensity of breathing such as dyspnea, gasping, and rales), and changes in food and water consumption. In addition, signs of lethargy and/or unresponsiveness and any clinical signs of more than slight or momentary pain and distress, or a >5% reduction in body weight from Day 1 to Day 6, and mortality should be considered in the evaluation. Moribund animals or animals obviously in pain or showing signs of severe and enduring distress should be humanely killed (37).

Main study experimental schedule

25. The experimental schedule of the assay is as follows:

- **Day 1:**
  Individually identify and record the weight of each animal and any clinical observation. Apply 25 µL of the appropriate dilution of the test substance, the vehicle alone, or the PC (concurrent or recent, based on laboratory policy in considering paragraphs 11-15), to the dorsum of each ear.

- **Days 2 and 3:**
  Repeat the application procedure carried out on Day 1.

- **Days 4 and 5:**
  No treatment.

- **Day 6:**
  Record the weight of each animal. Inject 250 µL of sterile phosphate-buffered saline (PBS) containing 20 µCi (7.4×10⁵ Bq) of tritiated (^3H)-methyl thymidine into all test and control mice via the tail vein. Alternatively, inject 250 µL sterile PBS containing 2 µCi (7.4×10⁶ Bq) of ^125I-iododeoxyuridine and 10⁻⁵M fluorodeoxyuridine into all mice via the tail vein. Five hours (5 h) later, humanely kill the animals. Excise the draining auricular lymph nodes from each mouse ear and process together in PBS for each animal (individual animal approach); alternatively excise and pool the lymph nodes from each ear in PBS for each treatment group (pooled treatment group approach). Details and diagrams of the lymph node identification and dissection can be found in reference (12). To further monitor the local skin response in the main study, additional parameters such as scoring of ear erythema or ear thickness measurements (obtained either by using a thickness gauge, or ear punch weight determinations at necropsy) may be included in the study protocol.
Preparation of cell suspensions

26. A single-cell suspension of lymph node cells (LNC) excised bilaterally using the individual animal approach or alternatively, the pooled treatment group approach is prepared by gentle mechanical disaggregation through 200 micron-mesh stainless steel gauze or another acceptable technique for generating a single-cell suspension. The LNC are washed twice with an excess of PBS and the DNA is precipitated with 5% trichloroacetic acid (TCA) at 4°C for 18h (3). Pellets are either re-suspended in 1 mL TCA and transferred to scintillation vials containing 10 mL of scintillation fluid for 3H-counting, or transferred directly to gamma counting tubes for 125I-counting.

Determination of cellular proliferation (incorporated radioactivity)

27. Incorporation of 3H-methyl thymidine is measured by β-scintillation counting as disintegrations per minute (DPM). Incorporation of 125I-iododeoxyuridine is measured by 125I-counting and also is expressed as DPM. Depending on the approach used, the incorporation is expressed as DPM/mouse (individual animal approach) or DPM/treatment group (pooled treatment group approach).

Reduced LLNA

28. In certain situations, when there is a regulatory need to confirm a negative prediction of skin sensitizing potential an optional rLLNA protocol (16) (17) (18) using fewer animals may be used, provided there is adherence to all other LLNA protocol specifications in this TG. Before applying the rLLNA approach, clear justifications and scientific rationale for its use should be provided. If a positive or equivocal result is obtained, additional testing may be needed in order to interpret or clarify the finding.

29. The reduction in number of dose groups is the only difference between the LLNA and the rLLNA test method protocols and for this reason the rLLNA does not provide dose-response information. Therefore, the rLLNA should not be used when dose-response information is needed. Like the multi-dose LLNA, the test substance concentration evaluated in the rLLNA should be the maximum concentration that does not induce overt systemic toxicity and/or excessive local skin irritation in the mouse (see paragraph 18).

OBSERVATIONS

Clinical observations

30. Each mouse should be carefully observed at least once daily for any clinical signs, either of local irritation at the application site or of systemic toxicity. All observations are systematically recorded with records being maintained for each mouse. Monitoring plans should include criteria to promptly identify those mice exhibiting systemic toxicity, excessive local skin irritation, or corrosion of skin for euthanasia (37).

Body weights

31. As stated in paragraph 25, individual animal body weights should be measured at the start of the test and at the scheduled humane kill.

CALCULATION OF RESULTS

32. Results for each treatment group are expressed as the SI. When using the individual animal approach, the SI is derived by dividing the mean DPM/mouse within each test substance group, and the PC
group, by the mean DPM/mouse for the solvent/VC group. The average SI for the VCs is then one. When using the pooled treatment group approach, the SI is obtained by dividing the pooled radioactive incorporation for each treatment group by the incorporation of the pooled VC group; this yields a mean SI.

33. The decision process regards a result as positive when $SI \geq 3$. However, the strength of the dose-response, the statistical significance and the consistency of the solvent/vehicle and PC responses may also be used when determining whether a borderline result is declared positive (4)(5)(6).

34. If it is necessary to clarify the results obtained, consideration should be given to various properties of the test substance, including whether it has a structural relationship to known skin sensitizers, whether it causes excessive local skin irritation in the mouse, and the nature of the dose-response relationship seen. These and other considerations are discussed in detail elsewhere (7).

35. Collecting radioactivity data at the level of the individual mouse will enable a statistical analysis for presence and degree of dose-response relationship in the data. Any statistical assessment could include an evaluation of the dose-response relationship as well as suitably adjusted comparisons of test groups (e.g. pair-wise dosed group versus concurrent VC comparisons). Statistical analyses may include, e.g. linear regression or William’s test to assess dose-response trends, and Dunnett’s test for pair-wise comparisons. In choosing an appropriate method of statistical analysis, the investigator should maintain an awareness of possible inequalities of variances and other related problems that may necessitate a data transformation or a non-parametric statistical analysis. In any case the investigator may need to carry out SI calculations and statistical analyses with and without certain data points (sometimes called “outliers”).

DATA AND REPORTING

Data

36. Data should be summarised in tabular form. When using the individual animal approach, show the individual animal DPM values, the group mean DPM/animal, its associated error term (e.g. SD, SEM), and the mean SI for each dose group compared against the concurrent VC group. When using the pooled treatment group approach, show the mean/median DPM and the mean SI for each dose group compared against the concurrent VC group.

Test report

37. The test report should contain the following information:

Test substance and control test substances:

- identification data (e.g. CAS number, if available; source; purity; known impurities; lot number);
- physical nature and physicochemical properties (e.g. volatility, stability, solubility);
- if formulation, composition and relative percentages of components;

Solvent/vehicle:

- identification data (purity; concentration, where appropriate; volume used);
- justification for choice of vehicle;

Test animals:
source of CBA mice;
– microbiological status of the animals, when known;
– number and age of animals;
– source of animals, housing conditions, diet, etc;

Test conditions:
– details of test substance preparation and application;
– justification for dose selection (including results from pre-screen test, if conducted);
– vehicle and test substance concentrations used, and total amount of test substance applied;
– details of food and water quality (including diet type/source, water source);
– details of treatment and sampling schedules;
– methods for measurement of toxicity;
– criteria for considering studies as positive or negative;
– details of any protocol deviations and an explanation on how the deviation affects the study design and results;

Reliability check:
– summary of results of latest reliability check, including information on test substance, concentration and vehicle used;
– concurrent and/or historical PC and concurrent NC data for testing laboratory;
– if a concurrent PC was not included, the date and laboratory report for the most recent periodic PC and a report detailing the historical PC data for the laboratory justifying the basis for not conducting a concurrent PC;

Results:
– individual weights of mice at start of dosing and at scheduled kill; as well as mean and associated error term (e.g. SD, SEM) for each treatment group;
– time course of onset and signs of toxicity, including dermal irritation at site of administration, if any, for each animal;
– a table of individual mouse (individual animal approach) or mean/median (pooled treatment group approach) DPM values and SI values for each treatment group;
– mean and associated error term (e.g. SD, SEM) for DPM/mouse for each treatment group and the results of outlier analysis for each treatment group when using the individual animal approach;
– calculated SI and an appropriate measure of variability that takes into account the inter-animal variability in both the test substance and control groups when using the individual animal approach;
– dose-response relationship;
– statistical analyses, where appropriate;

Discussion of results:
– a brief commentary on the results, the dose-response analysis, and statistical analyses, where appropriate, with a conclusion as to whether the test substance should be considered a skin sensitizer.
LITERATURE


(25) OECD (2002), Acute Dermal Irritation/Corrosion. OECD Guideline for Testing of Chemicals No. 404, Paris, France. Available at: [http://www.oecd.org/document/40/0,3343,en_2649_34377_37051368_1_1_1_1,00.html]


ANNEX 1

PERFORMANCE STANDARDS FOR ASSESSMENT OF PROPOSED SIMILAR OR MODIFIED LLNA TEST METHODS FOR SKIN SENSITIZATION

INTRODUCTION

1. The purpose of Performance Standards (PS) is to communicate the basis by which new test methods, both proprietary (i.e. copyrighted, trademarked, registered) and non-proprietary can be determined to have sufficient accuracy and reliability for specific testing purposes. These PS, based on validated and accepted test methods, can be used to evaluate the reliability and accuracy of other similar test methods (colloquially referred to as “me-too” tests) that are based on similar scientific principles and measure or predict the same biological or toxic effect (14).

2. Prior to adoption of modified test methods (i.e. proposed potential improvements to an approved test method), there should be an evaluation to determine the effect of the proposed changes on the test’s performance and the extent to which such changes affect the information available for the other components of the validation process. Depending on the number and nature of the proposed changes, the generated data and supporting documentation for those changes, they should either be subjected to the same validation process as described for a new test, or, if appropriate, to a limited assessment of reliability and relevance using established PS (14).

3. Similar or modified test methods proposed for use under this Test Guideline should be evaluated to determine their reliability and accuracy using chemicals representing the full range of the LLNA scores. To avoid unwarranted animal use, it is strongly recommended that model developers contact OECD before starting validation studies in accordance with the PS and guidance provided in this Test Guideline.

4. These PS are based on the US-ICCVAM, EC-ECVAM and Japanese-JaCVAM harmonised PS (12), for evaluating the validity of similar or modified versions of the LLNA. The PS consists of essential test method components, recommended reference substances, and standards for accuracy and reliability that the proposed test method should meet or exceed.

I. Essential test method components

5. To ensure that a similar or modified LLNA test method is functionally and mechanistically analogous to the LLNA and measures the same biological effect, the following components should be included in the test method protocol:

- The test substance should be applied topically to both ears of the mouse;
- Lymphocyte proliferation should be measured in the lymph nodes draining from the site of test substance application;
- Lymphocyte proliferation should be measured during the induction phase of skin sensitization;
- For test substances, the highest dose selected should be the maximum concentration that does not induce systemic toxicity and/or excessive local skin irritation in the mouse. For positive reference substances, the highest dose should be at least as high as the LLNA EC3 values of the corresponding reference test substances (see Table 1) without producing systemic toxicity and/or excessive local skin irritation in the mouse;
• A concurrent VC should be included in each study and, where appropriate, a concurrent PC should also be used;
• A minimum of four animals per dose group should be used;
• Either individual or pooled animal data may be collected.

If any of these criteria are not met, then these PS cannot be used for validation of the similar or modified test method.

II. Minimum list of reference substances

6. The US-ICCVAM, EC-ECVAM and Japanese-JaCVAM harmonized PS (12) identified 18 minimum reference substances that should be used and four optional reference substances (i.e. substances that produced either false positive or false negative results in the LLNA, when compared to human and guinea pig results (i.e. TG 406) (13), and therefore provide the opportunity to demonstrate equal to or better performance than the LLNA) that are included in the LLNA PS. The selection criteria for identifying these substances were:

• The list of reference substances represented the types of substances typically tested for skin sensitization potential and the range of responses that the LLNA is capable of measuring or predicting;
• The substances had well-defined chemical structures;
• LLNA data from guinea pig tests (i.e. TG 406) (13) and (where possible) data from humans were available for each substance; and
• The substances were readily available from a commercial source.

The recommended reference substances are listed in Table 1. Studies using the proposed reference substances should be evaluated in the vehicle with which they are listed in Table 1. In situations where a listed substance may not be available, other substances that meet the selection criteria mentioned may be used, with adequate justification.
TABLE 1: RECOMMENDED REFERENCE SUBSTANCES FOR THE LLNA PS.

<table>
<thead>
<tr>
<th>Number</th>
<th>Substance</th>
<th>CAS No</th>
<th>Form</th>
<th>Veh</th>
<th>EC3 %</th>
<th>N</th>
<th>0.5x - 2.0x EC3</th>
<th>Actual EC3 Range</th>
<th>LLNA vs. GP</th>
<th>LLNA vs. Human</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5-Chloro-2-methyl-4-isothiazolin-3-one (CMI)/2-methyl-4-isothiazolin-3-one (MI)</td>
<td>26172-55-4/2682-20-4</td>
<td>Liq DMF</td>
<td>0.009</td>
<td>1</td>
<td>0.0045-0.018</td>
<td>NC</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>DNCB</td>
<td>97-00-7</td>
<td>Sol AOO</td>
<td>0.049</td>
<td>15</td>
<td>0.025-0.099</td>
<td>0.02-0.094</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>4-Phenylenediamine</td>
<td>106-50-3</td>
<td>Sol AOO</td>
<td>0.11</td>
<td>6</td>
<td>0.055-0.22</td>
<td>0.07-0.16</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Cobalt chloride</td>
<td>7646-79-9</td>
<td>Sol DMSO</td>
<td>0.6</td>
<td>2</td>
<td>0.3-1.2</td>
<td>0.4-0.8</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Isoeugenol</td>
<td>97-54-1</td>
<td>Liq AOO</td>
<td>1.5</td>
<td>47</td>
<td>0.77-3.1</td>
<td>0.5-3.3</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2-Mercaptobenzothiazole</td>
<td>149-30-4</td>
<td>Sol DMF</td>
<td>1.7</td>
<td>1</td>
<td>0.85-3.4</td>
<td>NC</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Citral</td>
<td>5392-40-5</td>
<td>Liq AOO</td>
<td>9.2</td>
<td>6</td>
<td>4.6-18.3</td>
<td>5.1-13</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>HCA</td>
<td>101-86-0</td>
<td>Liq AOO</td>
<td>9.7</td>
<td>21</td>
<td>4.8-19.5</td>
<td>4.4-14.7</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Eugenol</td>
<td>97-53-0</td>
<td>Liq AOO</td>
<td>10.1</td>
<td>11</td>
<td>5.05-20.2</td>
<td>4.9-15</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Phenyl benzoate</td>
<td>93-99-2</td>
<td>Sol AOO</td>
<td>13.6</td>
<td>3</td>
<td>6.8-27.2</td>
<td>1.2-20</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Cinnamic alcohol</td>
<td>104-54-1</td>
<td>Sol AOO</td>
<td>21</td>
<td>1</td>
<td>10.5-42</td>
<td>NC</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Imidazolidinyl urea</td>
<td>39236-46-9</td>
<td>Sol DMSO</td>
<td>24</td>
<td>1</td>
<td>12-48</td>
<td>NC</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Methyl methacrylate</td>
<td>80-62-6</td>
<td>Liq AOO</td>
<td>90</td>
<td>1</td>
<td>45-100</td>
<td>NC</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Chlorobenzene</td>
<td>108-90-7</td>
<td>Liq AOO</td>
<td>25</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>-/-</td>
<td>-/*</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Isopropanol</td>
<td>67-63-0</td>
<td>Liq AOO</td>
<td>50</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>-/-</td>
<td>-/*</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Lactic acid</td>
<td>50-21-5</td>
<td>Liq DMSO</td>
<td>25</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>-/-</td>
<td>-/*</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Methyl salicylate</td>
<td>119-36-8</td>
<td>Liq AOO</td>
<td>20</td>
<td>9</td>
<td>NA</td>
<td>NA</td>
<td>-/-</td>
<td>-/-</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Salicylic acid</td>
<td>69-72-7</td>
<td>Sol AOO</td>
<td>25</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>-/-</td>
<td>-/-</td>
<td></td>
</tr>
</tbody>
</table>
### Optional Substances to Demonstrate Improved Performance Relative to the LLNA

<table>
<thead>
<tr>
<th>Number</th>
<th>Substance¹</th>
<th>CAS No</th>
<th>Form</th>
<th>Veh²</th>
<th>EC3 %³</th>
<th>Actual EC3 Range</th>
<th>LLNA vs. GP</th>
<th>LLNA vs. Human</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>Sol DMF</td>
<td>8.1</td>
<td>5</td>
<td>4.05-16.2</td>
<td>1.5-17.1</td>
<td>+/-</td>
</tr>
<tr>
<td>20</td>
<td>Ethylene glycol dimethacrylate</td>
<td>97-90-5</td>
<td>Liq MEK</td>
<td>28</td>
<td>1</td>
<td>14-56</td>
<td>NC</td>
<td>+/-</td>
</tr>
<tr>
<td>21</td>
<td>Xylene</td>
<td>1330-20-7</td>
<td>Liq AOO</td>
<td>95.8</td>
<td>1</td>
<td>47.9-100</td>
<td>NC</td>
<td>+/-</td>
</tr>
<tr>
<td>22</td>
<td>Nickel chloride</td>
<td>7718-54-9</td>
<td>Sol DMSO</td>
<td>5</td>
<td>2</td>
<td>NA</td>
<td>NA</td>
<td>+/-</td>
</tr>
</tbody>
</table>

Abbreviations: AOO = acetone: olive oil (4:1, v/v); CAS No = Chemical Abstracts Service Number; DMF = N,N-dimethylformamide; DMSO = dimethyl sulfoxide; DNCB = 2,4-dinitrochlorobenzene; EC3 = estimated concentration needed to produce a stimulation index of 3; GP = guinea pig test result (i.e. TG 406) (13); HCA = hexyl cinnamic aldehyde; Liq = liquid; LLNA = murine local lymph node assay result (i.e. TG 429) (1); MEK = methyl ethyl ketone; NA = not applicable since stimulation index <3; NC = not calculated since data was obtained from a single study; Sol = solid; Veh = test vehicle.

1 Test substances should be prepared daily unless stability data demonstrate the acceptability of storage.

2 Because of the potential impact of different vehicles on the performance of the LLNA, the recommended vehicle for each reference substance should be used (24)(32).

3 Mean value where more than one EC3 value was available. For negative substances (i.e. with stimulation index <3, the highest concentration tested is provided.

4 Number of LLNA studies from which data were obtained.

5 Commercially available as Kathon CG (CAS No 55965-84-9), which is a 3:1 mixture of CMI and MI. The relative concentrations of each component range from 1.1% to 1.25% (CMI) and 0.3% to 0.45% (MI). The inactive components are magnesium salts (21.5% to 24%) and copper nitrate (0.15% to 0.17%), with the remaining formulation 74% to 77% water. Kathon CG is readily available through Sigma-Aldrich and Rohm and Haas (now Dow Chemical Corporation).

* = Presumed to be a non-sensitizer in humans based on the fact that no clinical patch test results were located, it is not included in a patch test kit allergen, and no case reports of human sensitisation were located.

** = GP data not available.
III. Defined reliability and accuracy standards

7. The accuracy of a similar or modified LLNA test method should meet or exceed that of the LLNA PS when it is evaluated using the 18 minimum reference substances that should be used. The new or modified test method should result in the correct classification based on a “yes/no” decision. However, the new or modified test method might not correctly classify all of the minimum reference substances that should be used. If, for example, one of the weak sensitizers were misclassified, a rationale for the misclassification and appropriate additional data (e.g. test results that provide correct classifications for other substances with physical, chemical, and sensitizing properties similar to those of the misclassified reference substance) could be considered to demonstrate equivalent performance. Under such circumstances, the validation status of the new or modified LLNA test method would be evaluated on a case-by-case basis.

Intra-laboratory reproducibility

8. To determine intra-laboratory reproducibility, a new or modified LLNA test method should be assessed using a sensitizing substance that is well characterized in the LLNA. Therefore, the LLNA PS are based on the variability of results from repeated tests of hexyl cinnamic aldehyde (HCA). To assess intra-laboratory reliability, threshold estimated concentration (ECt) values for HCA should be derived on four separate occasions with at least one week between tests. Acceptable intra-laboratory reproducibility is indicated by a laboratory’s ability to obtain, in each HCA test, ECt values between 5% and 20%, which represents the range of 0.5-2.0 times the mean EC3 specified for HCA (10%) in the LLNA (see Table 1).

Inter-laboratory reproducibility

9. Inter-laboratory reproducibility of a new or modified LLNA test method should be assessed using two sensitizing substances that are well characterized in the LLNA. The LLNA PS are based on the variability of results from tests of HCA and 2,4-dinitrochlorobenzene (DNCB) in different laboratories. ECt values should be derived independently from a single study conducted in at least three separate laboratories. To demonstrate acceptable inter-laboratory reproducibility, each laboratory should obtain ECt values of 5% to 20% for HCA and 0.025% to 0.1% for DNCB, which represents the range of 0.5-2.0 times the mean EC3 concentrations specified for HCA (10%) and DNCB (0.05%), respectively, in the LLNA (see Table 1).
ANNEX 2

DEFINITIONS

**Accuracy**: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (14).

**Benchmark test substance**: A sensitizing or non-sensitizing substance used as a standard for comparison to a test substance. A benchmark substance should have the following properties; (i) consistent and reliable source(s); (ii) structural and functional similarity to the class of substances being tested; (iii) known physical/chemical characteristics; (iv) supporting data on known effects, and (v) known potency in the range of the desired response.

**Estimated concentration threshold (ECT)**: Estimated concentration of a test substance needed to produce a stimulation index that is indicative of a positive response.

**Estimated concentration three (EC3)**: Estimated concentration of a test substance needed to produce a stimulation index of three.

**False negative**: A test substance incorrectly identified as negative or non-active by a test method, when in fact it is positive or active.

**False positive**: A test substance incorrectly identified as positive or active by a test, when in fact it is negative or non-active.

**Hazard**: The potential for an adverse health or ecological effect. The adverse effect is manifested only if there is an exposure of sufficient level.

**Inter-laboratory reproducibility**: A measure of the extent to which different qualified laboratories, using the same protocol and testing the same test substances, can produce qualitatively and quantitatively similar results. Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (14).

**Intra-laboratory reproducibility**: A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times. Also referred to as within-laboratory reproducibility (14).

**Me-too test**: A colloquial expression for a test method that is structurally and functionally similar to a validated and accepted reference test method. Such a test method would be a candidate for catch-up validation. Interchangeably used with similar test method (14).

**Outlier**: An outlier is an observation that is markedly different from other values in a random sample from a population.

**Performance standards (PS)**: Standards, based on a validated test method, that provide a basis for evaluating the comparability of a proposed test method that is functionally and mechanistically similar. Included are; (i) essential test method components; (ii) a minimum list of Reference Chemicals selected
from among the chemicals used to demonstrate the acceptable performance of the validated test method; and (iii) the similar levels of accuracy and reliability, based on what was obtained for the validated test method, that the proposed test method should demonstrate when evaluated using the minimum list of Reference Chemicals (14).

**Proprietary test method:** A test method for which manufacture and distribution is restricted by patents, copyrights, trademarks, etc.

**Quality assurance:** A management process by which adherence to laboratory testing standards, requirements, and record keeping procedures, and the accuracy of data transfer, are assessed by individuals who are independent from those performing the testing.

**Reference chemicals:** Chemicals selected for use in the validation process, for which responses in the *in vitro* or *in vivo* reference test system or the species of interest are already known. These chemicals should be representative of the classes of chemicals for which the test method is expected to be used, and should represent the full range of responses that may be expected from the chemicals for which it may be used, from strong, to weak, to negative. Different sets of reference chemicals may be required for the different stages of the validation process, and for different test methods and test uses (14).

**Relevance:** Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method (14).

**Reliability:** Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility (14).

**Skin sensitization:** An immunological process that results when a susceptible individual is exposed topically to an inducing chemical allergen, which provokes a cutaneous immune response that can lead to the development of contact sensitization.

**Stimulation Index (SI):** A value calculated to assess the skin sensitization potential of a test substance that is the ratio of the proliferation in treated groups to that in the concurrent vehicle control group.

**Test substance:** Any material tested using this TG, whether it is a single compound or consists of multiple components (*e.g.* final products, formulations). When testing formulations, consideration should be given to the fact that certain regulatory authorities only require testing of the final product formulation. However, there may also be testing requirements for the active ingredient(s) of a product formulation.

**Validated test method:** A test method for which validation studies have been completed to determine the relevance (including accuracy) and reliability for a specific purpose. It is important to note that a validated test method may not have sufficient performance in terms of accuracy and reliability to be found acceptable for the proposed purpose (14).